Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CS 917

Drug Profile

CS 917

Alternative Names: CS-917; MB 6322; MB06322

Latest Information Update: 23 Jan 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Daiichi Sankyo Inc; Metabasis Therapeutics
  • Class Amino acids; Antihyperglycaemics; Organophosphorus compounds; Small molecules
  • Mechanism of Action Fructose bisphosphatase inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 29 Jun 2007 Data presented at the 67th Scientific Sessions of the American Diabetes Association (ADA-2007) added to the Diabetes pharmacodynamics section
  • 26 Jun 2007 Daiichi Sankyo completes a phase IIb trial in Diabetes in the US
  • 01 Feb 2007 Daiichi Sankyo completes enrolment in its phase IIb trial for Type-2 diabetes in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top